Tuesday, July 8, 2025
12.7 C
London
HomeFinTechPharmAust: Gets approval to increase dosage in MPL trial

PharmAust: Gets approval to increase dosage in MPL trial

Date:

Mastercard and Pay4You Unite for Enhanced Spend Management Solutions

A Game-Changing Partnership to Transform Financial Oversight for BusinessesHighlights:...

EPC Urges Directory Service Providers to Collaborate on VOP Scheme

Enhancing the Future of Payments: A Call for Collaboration...

Five More Belgian Banks Join the European Payments Initiative

Enhancing Collaboration in the Payment Landscape Across EuropeHighlights: Five...

PharmAust Gets approval to increase dosage in MPL trial

  • PharmAust (PAA) has received the green light from the trial safety committee to increase the tablet dosage in its motor neurone disease study
  • The company reported no safety issues or serious adverse events found during its study, as a result of the treatment
  • The company says it will continue supplying MPL tablets to all six patients in cohort one, with a four-week escalating dose of the MPL tablets set to begin
  • Patient recruitment for the next stage MPL dosing level has started, with four new patients currently undergoing screening
  • The company shares were up 1.15 per cent, trading at 8.8 cents at 1:15 pm AEDT

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories